Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Inclusion Criteria: * Patients must have histologically documented adenocarcinoma of the prostate with progressive systemic (metastatic) disease despite castrate levels of testosterone due to orchiectomy or LHRH agonist (which must be continued); castrate levels of testosterone must be maintained * At the time of enrollment, patients must have evidence of metastatic disease, either: * Measurable disease (with any PSA) OR * Non-measurable disease with PSA \>= 5 ng/ml; patients with PSA \>= 5 ng/ml only are not eligible DEFINITION OF MEASURABLE DISEASE/TARGET LESIONS * Any lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques: 1) physical exam for clinically palpable lymph nodes and superficial skin lesions, 2) chest X-ray for clearly defined lung lesions surrounded by aerated lung OR those lesions measured as \>= 10 mm with a spiral CT scan or MRI * Measurable lesions (up to a maximum of 10 in number) representative of all organs involved to be identified as target lesions; the sum of the longest diameters (LD) for all target lesions will be calculated and reported as baseline sum LD * If measurable disease is confined to a solitary lesion then its neoplastic nature will need to be confirmed by histology * Ultrasound may not be used to measure tumor lesions that are not easily accessible clinically DEFINITION OF NON-MEASURABLE DISEASE/NON-TARGET LESIONS * Non-target lesions include all other lesions, including small lesions with longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT scan and truly non-measurable lesions, which include: * Bone lesions * Pleural or pericardial effusions, ascites * CNS lesions, leptomeningeal disease * Irradiated lesions, unless progression documented after RT * Patients must have demonstrated evidence of progressive disease since the most recent change in therapy; progressive disease is defined as any one of the following (measurable disease, bone scan, or PSA progression): * MEASURABLE DISEASE PROGRESSION: Objective evidence of increase \> 20% in the sum of the longest diameters (LD) of target lesions from the time of maximal regression or the appearance of one or more new lesions * BONE SCAN PROGRESSION: Appearance of one or more new lesions on bone scan attributable to prostate cancer along with a PSA \>= 5 ng/ml will constitute progression * PSA PROGRESSION: An elevated PSA (at least \>= 5 ng/ml) which has risen serially from baseline on two occasions each at least one week apart. If the confirmatory PSA (#3) value is less (i.e., #3b) than screening PSA (#2) value, then an additional test for rising PSA (#4) will be required to document progression * Failure despite standard androgen deprivation therapy * Flutamide and megestrol acetate (any dose) must be discontinued at least 4 weeks prior to registration; bicalutamide and nilutamide must be discontinued at least 6 weeks prior to registration. If improvement following antiandrogen withdrawal is noted, progression must be established using the criteria above; primary testicular androgen suppression (e.g., with an LHRH analogue) should not be discontinued * At least 4 weeks since any hormonal therapy, including ketoconazole, aminoglutethimide, systemic steroids (any dose), megestrol acetate (any dose) * No prior cytotoxic chemotherapy, including estramustine or suramin * No prior anti-angiogenesis agents, including thalidomide and bevacizumab * \>= 4 weeks since major surgery and fully recovered * \>= 4 weeks since any prior radiation and fully recovered * \>= 8 weeks since the last dose of strontium-89 or Samarium * Patients receiving bisphosphonate therapy prior to initiating protocol treatment must have received bisphosphonates for at least 1 month and have progressive disease despite this therapy * CTC (ECOG) performance status: 0-2 * No myocardial infarction or significant change in anginal pattern within one year or current congestive heart failure (NYHA Class 2 or higher) * No deep venous thrombosis or pulmonary embolus within one year. No need for full-dose oral or parenteral anticoagulation; daily prophylactic aspirin is allowed * No clinically significant peripheral neuropathy * Granulocytes \>= 1500/ul * Platelet count \>= 100,000/ul * Creatinine =\< 1.5 x upper limit of normal * Bilirubin =\< 1.0 x upper limit of normal * AST =\< 1.5 x upper limits of normal * Urinalysis =\< 1 + protein on dipstick * PSA \>= 5 ng/ml (if non-measurable disease) * Serum Testosterone =\< 50 ng/ml for patients who have not had bilateral orchiectomy